NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Wednesday that it expects to report third-quarter revenues of between $79 million and $81 million, below its own target range and Wall Street's average estimate of $83.8 million.

The Sunnyvale, Calif.-based firm said the shortfall is due to "intermittent interruptions in the supply of Xpert cartridge parts." The Xpert cartridges contain the tests that run on the firm's GeneXpert systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.